UCB showcases decade of growth and Patient Value Strategy driving differentiated innovation

UCB showcases decade of growth and Patient Value Strategy driving differentiated innovation

• Breakthrough innovation, differentiated solutions and cutting-edge pipeline to unlock growth for a decade+ and beyond
• In the United States, BIMZELX^® achieves significantly improved access for patients as of January 2025
• UCB commitment to improving lives of people living with severe diseases through innovative medicines and a sustainable, patient-centered approach

Brussels (Belgium), January 15, 2025 – 7:00 CET –UCB (Euronext: UCB), a global biopharmaceutical leader dedicated to transforming the lives of people living with severe diseases, presents today its growth journey and the strategic priorities driving its success into the future at the 43rd J.P. Morgan Healthcare Conference in San Francisco, U.S. Over the past decade, UCB has focused on developing solutions in immunology and neurology, driven by its patient value strategy. Going ahead, UCB expects a decade-plus of growth.

Delivering on Ambitions    

With nearly 100 years of excellence in biopharmaceuticals, UCB has built a legacy of patient-centered innovation. The company’s Patient Value Strategy has driven the development of transformative medicines, enabling a decade plus of growth and setting the stage for continued success.

“At UCB, we are looking ahead with confidence and determination. We will continue to deliver differentiated innovation, transforming what is possible for patients, caregivers, medical professionals and shareholders. Guided by our Patient Value Strategy, we are committed to delivering solutions that truly make a difference, while ensuring a sustainable and inclusive future for all,” said Jean-Christophe Tellier, CEO of UCB. 

Key highlights from the presentation    

• BIMZELX^® (bimekizumab) now has significantly improved insurance coverage in the U.S., making it easier for patients to access and afford. BIMZELX^® is available to patients in 48 countries.
• RYSTIGGO^® (rozanolixizumab) and ZILBRYSQ^® (zilucoplan): UCB is the first and only company with a differentiated gMG portfolio and market authorization in more than 20 countries. 
• R&D Leadership: Industry-leading productivity has resulted in multiple positive Phase 3 results, 25 approvals and launches across major regions, including the U.S., EU, and Japan, in the last 24 months.
• Sustainability Excellence: UCB is one of only few biopharma companies with validated net-zero targets by the Science Based Targets initiative (SBTi), which underscores its commitment to environmental and societal well-being.
• Financial Growth: As per guidance update in November 2024 and for 2024, UCB is expecting revenue near €6 billion and an adjusted EBITDA margin within the upper part of the range of 23.0-24.5%. Full year 2024 financial results will be announced on February 27, 2025.

Confidence in a future of sustained growth    

UCB aims to continue its growth by focusing on innovative medicines that make a real difference for patients, caregivers, and medical professionals. The company is dedicated to creating a sustainable and inclusive future for all.

The CEO's presentation and webcast at the J.P. Morgan conference will be available this evening on the UCB website in the Investor Relations section. 

For further information, contact UCB: 

Investor Relations
Antje Witte
T: +32.2.559.94.14 
Email: antje.witte@ucb.com 

Sahar Yazdian
T: +32 2 559 9137
sahar.yazdian@ucb.com 

Corporate Communications
Laurent Schots 
T: +32.2.559.92.64 
Email:  laurent.schots@ucb.com

About UCB 
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 9 000 people in approximately 40 countries, the company generated revenue of € 5.3 billion in 2023. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on X: @UCB_news